781 related articles for article (PubMed ID: 25800206)
1. C1-inhibitor polymers activate the FXII-dependent kallikrein-kinin system: Implication for a role in hereditary angioedema.
Madsen DE; Sidelmann JJ; Biltoft D; Gram J; Hansen S
Biochim Biophys Acta; 2015 Jun; 1850(6):1336-42. PubMed ID: 25800206
[TBL] [Abstract][Full Text] [Related]
2. Kallikrein-kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys.
Bork K; Kleist R; Hardt J; Witzke G
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):325-32. PubMed ID: 19474702
[TBL] [Abstract][Full Text] [Related]
3. Presence of C1-inhibitor polymers in a subset of patients suffering from hereditary angioedema.
Madsen DE; Hansen S; Gram J; Bygum A; Drouet C; Sidelmann JJ
PLoS One; 2014; 9(11):e112051. PubMed ID: 25369003
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
Kaplan AP; Joseph K
Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213
[TBL] [Abstract][Full Text] [Related]
5. Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II.
Joseph K; Tholanikunnel BG; Bygum A; Ghebrehiwet B; Kaplan AP
J Allergy Clin Immunol; 2013 Aug; 132(2):470-5. PubMed ID: 23672780
[TBL] [Abstract][Full Text] [Related]
6. Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment.
Zeerleder S; Levi M
Ann Med; 2016; 48(4):256-67. PubMed ID: 27018196
[TBL] [Abstract][Full Text] [Related]
7. Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis.
Joseph K; Tholanikunnel TE; Kaplan AP
Ann Allergy Asthma Immunol; 2010 Jan; 104(1):50-4. PubMed ID: 20143645
[TBL] [Abstract][Full Text] [Related]
8. A novel assay to diagnose hereditary angioedema utilizing inhibition of bradykinin-forming enzymes.
Joseph K; Bains S; Tholanikunnel BG; Bygum A; Aabom A; Koch C; Farkas H; Varga L; Ghebrehiwet B; Kaplan AP
Allergy; 2015 Jan; 70(1):115-9. PubMed ID: 25186184
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12.
Bhattacharjee G; Revenko AS; Crosby JR; May C; Gao D; Zhao C; Monia BP; MacLeod AR
Nucleic Acid Ther; 2013 Jun; 23(3):175-87. PubMed ID: 23582057
[TBL] [Abstract][Full Text] [Related]
10. Coagulation Factor XII Gene Mutation in Brazilian Families with Hereditary Angioedema with Normal C1 Inhibitor.
Moreno AS; Valle SO; Levy S; França AT; Serpa FS; Arcuri HA; Palma MS; Campos WN; Dias MM; Ponard D; Monnier N; Lunardi J; Bork K; Silva WA; Arruda LK
Int Arch Allergy Immunol; 2015; 166(2):114-20. PubMed ID: 25790805
[TBL] [Abstract][Full Text] [Related]
11. Hereditary angioedema: Pathophysiology (HAE type I, HAE type II, and HAE nC1-INH).
Wedner HJ
Allergy Asthma Proc; 2020 Nov; 41(Suppl 1):S14-S17. PubMed ID: 33109319
[TBL] [Abstract][Full Text] [Related]
12. Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations.
Bork K; Wulff K; Witzke G; Hardt J
Allergy; 2015 Aug; 70(8):1004-12. PubMed ID: 25952149
[TBL] [Abstract][Full Text] [Related]
13. Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor.
Bova M; Suffritti C; Bafunno V; Loffredo S; Cordisco G; Del Giacco S; De Pasquale TMA; Firinu D; Margaglione M; Montinaro V; Petraroli A; Radice A; Brussino L; Zanichelli A; Zoli A; Cicardi M
Allergy; 2020 Jun; 75(6):1394-1403. PubMed ID: 31860755
[TBL] [Abstract][Full Text] [Related]
14. A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain.
Ivanov I; Matafonov A; Sun MF; Mohammed BM; Cheng Q; Dickeson SK; Kundu S; Verhamme IM; Gruber A; McCrae K; Gailani D
Blood; 2019 Mar; 133(10):1152-1163. PubMed ID: 30591525
[TBL] [Abstract][Full Text] [Related]
15. Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert
Bouillet L; Boccon-Gibod I; Gompel A; Floccard B; Martin L; Blanchard-Delaunay C; Launay D; Fain O
Eur J Dermatol; 2017 Apr; 27(2):155-159. PubMed ID: 28251901
[TBL] [Abstract][Full Text] [Related]
16. Biochemistry, molecular genetics, and clinical aspects of hereditary angioedema with and without C1 inhibitor deficiency.
Miyata T; Horiuchi T
Allergol Int; 2023 Jul; 72(3):375-384. PubMed ID: 37169642
[TBL] [Abstract][Full Text] [Related]
17. Hereditary angioedema: the plasma contact system out of control.
De Maat S; Hofman ZLM; Maas C
J Thromb Haemost; 2018 Sep; 16(9):1674-1685. PubMed ID: 29920929
[TBL] [Abstract][Full Text] [Related]
18. Ongoing contact activation in patients with hereditary angioedema.
Konings J; Cugno M; Suffritti C; Ten Cate H; Cicardi M; Govers-Riemslag JW
PLoS One; 2013; 8(8):e74043. PubMed ID: 24013493
[TBL] [Abstract][Full Text] [Related]
19. Hereditary angioedema with F12 mutation: factors modifying the clinical phenotype.
Charignon D; Ghannam A; Defendi F; Ponard D; Monnier N; López Trascasa M; Launay D; Caballero T; Djenouhat K; Fain O; Cichon S; Martin L; Drouet C
Allergy; 2014 Dec; 69(12):1659-65. PubMed ID: 25134986
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Hereditary Angioedema.
Caballero T
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):1-16. PubMed ID: 33602658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
